FDA Exploring Whether Public Shaming Can Stop REMS Abuses
Executive Summary
Commissioner Gottlieb says agency is considering publicizing letters it has written to brand companies indicating it would not violate a REMS to sell a generic company samples for testing.
You may also be interested in...
In Switching Generic 'Reviews' To 'Assessments' Is US FDA Changing More Than Just A Word?
MaPP revision may be just a better description of ANDA evaluations – or indicative of a broad culture change, experts tell the Pink Sheet.
In Switching Generic 'Reviews' To 'Assessments' Is US FDA Changing More Than Just A Word?
MaPP revision may be just a better description of ANDA evaluations – or indicative of a broad culture change, experts tell the Pink Sheet.